Results 211 to 220 of about 164,505 (264)

Successful allo‐hematopoietic stem cell transplantation using washed hematopoietic stem cells in a pediatric patient complicated by acute myeloid leukemia and severe anaphylaxis to blood product

Pediatric Investigation, EarlyView.
Jieyu Tian, Guanghua Zhu, Maoquan Qin, Chenguang Jia, Shuxuan Ma, Bin Wang, Yanhui Luo   +6 more
wiley   +1 more source

Building a precision therapeutics program at a tertiary care children's hospital

Pediatric Investigation, EarlyView.
Luke Hamilton, Heidi Trinkman, Diana Carrasco, Kaitlin Smith, Kelly Vallance, Alejandra Dominguez, Danielle Miller, Megan Gibbs, Anish Ray   +8 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Venetoclax in acute myeloid leukemia

Expert Opinion on Investigational Drugs, 2023
Background: Substantial progress in the therapeutic arsenal used to treat acute myeloid leukemia became possible in the last decade, as a result of advances in gene editing and descriptive and functional genomics. Objective: The aim of this study is to analyze the efficacy and safety of venetoclax in the treatment of acute myeloid leukemia ...
Bruzzese, Antonella, Martino, Enrica Antonia, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Neri, Antonino, Morabito, Fortunato, Vigna, Ernesto, Gentile, Massimo   +8 more
openaire   +4 more sources

Acute Myeloid Leukemia

Journal of the National Comprehensive Cancer Network, 2008
Approximately 13,290 people will be diagnosed with acute myeloid leukemia (AML) in 2008, and 8820 patients will die of the disease. As the population ages, the incidence of AML, along with myelodysplasia, appears to be rising. Clinical trials have led to significant treatment improvements in some areas, primarily acute promyelocytic leukemia.
Margaret R, O'Donnell, Frederick R, Appelbaum, Steven E, Coutre, Lloyd E, Damon, Harry P, Erba, James, Foran, Jeffrey, Lancet, Lori J, Maness, Guido, Marcucci, Peter G, Maslak, Michael, Millenson, Joseph O, Moore, Farhad, Ravandi, Friedrich, Schuening, Paul, Shami, B Douglas, Smith, Richard M, Stone, Martin S, Tallman, Eunice, Wang, Frank L, White   +19 more
openaire   +5 more sources

Acute Myeloid Leukemia

Hematology, 2001
AbstractThrough the hard work of a large number of investigators, the biology of acute myeloid leukemia (AML) is becoming increasingly well understood, and as a consequence, new therapeutic targets have been identified and new model systems have been developed for testing novel therapies.
F R, Appelbaum, J M, Rowe, J, Radich, J E, Dick   +3 more
openaire   +2 more sources

Acute Myeloid Leukemia

Hematology/Oncology Clinics of North America, 2009
The evolution of acute myeloid leukemia (AML) classification reflects greater understanding of the AML pathogenesis. The 2008 World Health Organization classification incorporated cytogenetic and molecular genetic findings and introduced important prognostic correlations.
Amy, Heerema-McKenney, Daniel A, Arber
openaire   +2 more sources

Acute Myeloid Leukemia

Hematology, 2002
AbstractIn this chapter, Drs. Keating and Willman review recent advances in our understanding of the pathophysiology of acute myeloid leukemia (AML) and allied conditions, including the advanced myelodysplastic syndromes (MDS), while Drs. Goldstone, Avivi, Giles, and Kantarjian focus on therapeutic data with an emphasis on current patient care and ...
Francis J, Giles, Armand, Keating, Anthony H, Goldstone, Irit, Avivi, Cheryl L, Willman, Hagop M, Kantarjian   +5 more
openaire   +2 more sources

Metabolomics in acute myeloid leukemia

Molecular Genetics and Metabolism, 2020
Acute myeloid leukemia (AML) is a complex, heterogenous hematological malignancy caused by mutations in myeloid differentiation and proliferation. Response to therapy and long-term outcomes vary widely based on chromosomal and molecular aberrations. Many platforms have been used to characterize and stratify AML.
Anna V, Wojcicki, Maya M, Kasowski, Kathleen M, Sakamoto, Norman, Lacayo   +3 more
openaire   +2 more sources

SEPHguarding acute myeloid leukemia

Cell Stem Cell, 2022
Adaptive aberrant gene regulation is a hallmark of malignant growth and therapy resistance in acute myeloid leukemia (AML). In this issue of Cell Stem Cell, Eagle et al. identified oncogenic enhancer-driven overexpression of selenophosphate synthetase 2 (SEPHS2) as an opportunity for targeted mitigation of malignant cell growth in AML.
Malini, Gupta, Britta, Will
openaire   +2 more sources